New features include an injection port for small volume additions, a sub-surface fluid port for either addition or removal, and an extra port for the insertion of a third probe. The enhanced version replaces the first-generation Mobius launched in 2009.
Andrew Bulpin, head of services and solutions, Process Solutions, at EMD Millipore, said the enhanced operational and process monitoring capabilities in the new version would enable operations such as perfusion and monitoring of additional cell culture parameters such as carbon dioxide, viable cell density or optical density.
Designed to replace traditional glass benchtop bioreactors, the Mobius CellReady 3L Bioreactor has a standard stirred-tank format for use in development and optimisation of cell culture processes.
According to Millipore, by eliminating time-consuming steps associated with cleaning, assembly, and sterilisation, the Mobius CellReady 3L bioreactor significantly reduces the turnaround time typically associated with glass bioreactors.
Millipore upgrades Mobius CellReady Bioreactor
Offers increased operational flexibility and enhanced process monitoring
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Read moreHans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
Manufacturing
Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe
After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region